Back to top
more

ConforMIS, Inc. (CFMS)

(Delayed Data from NSDQ)

$2.66 USD

2.66
1,165,738

+0.22 (9.02%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

STERIS (STE) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS (STE) backed by elevated consumer demand and strong segmental growth in third-quarter fiscal 2021.

Globus Medical (GMED) Simplifies Spine Surgery With CREO ONE

by Zacks Equity Research

Globus Medical's (GMED) latest development to robotically navigated spine surgery will enable surgeons to maintain the navigational accuracy without performing traditional pedicle preparation.

Walgreens (WBA) Extends COVID-19 Vaccination to 49 States

by Zacks Equity Research

Walgreens (WBA) continues to expand access to COVID-19 vaccination in medically underserved communities and has surpassed 11 million administrations to date.

Here's Why You Should Hold on to STERIS (STE) Stock Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to strong segmental performance amid the pandemic and huge growth potential in healthcare and pharmaceutical industries.

Abbott (ABT) Gets Europe Nod for TriClip G4 to Treat TR

by Zacks Equity Research

Per Abbott's (ABT) TRILUMINATE CE Mark study, the latest version shows sustained symptomatic improvement, reduction in the severity of TR and improvement in functional status.

Quest Diagnostics (DGX) Rides on Test Sales Amid Volume Woe

by Zacks Equity Research

Quest Diagnostics (DGX) enters into an agreement with the CDC to provide genomic sequencing to identify new mutations in and patterns of transmission of SARS-CoV-2.

Orthofix (OFIX) Wins FDA Clearance for CONSTRUX Mini Ti System

by Zacks Equity Research

Orthofix's (OFIX) CONSTRUX Mini Ti Spacer System, designed with nanoscale surface is the first 3D-printed titanium interbody, was launched to enhance ACDF procedures.

Here's Why You Should Retain Integra LifeSciences (IART) Stock

by Zacks Equity Research

Investors are optimistic about Integra LifeSciences (IART) stock, owing to its strong international business growth and focus on portfolio optimization.

Varian Medical (VAR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Varian Medical (VAR) is optimistic about its prospective acquisitions and strength in Proton Therapy segment.

Will Walgreens Boots' (WBA) Retail Arm be Dull in Q2 Earnings?

by Zacks Equity Research

Walgreens Boots' (WBA) Retail Pharmacy International sales are likely to have remained dull in Q2 on difficult global market scenario.

Medtronic (MDT) Directional Lead for DBS System Gets CE Mark

by Zacks Equity Research

This SenSight system according to Medtronic (MDT), is set to enhance detection of local field potentials (LFPs).

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Hologic (HOLX) on its strong molecular diagnostic growth and robust international performance.

Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) backed by robust CAG and LPD revenues growth and strong global performance boosting the top line.

ConforMIS (CFMS) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

ConforMIS (CFMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Integra (IART) Neurosurgery Grows Sequentially Amid Supply Woe

by Zacks Equity Research

Most of Integra's (IART) franchises or products succeed in sustaining the momentum after returning to growth in the third quarter.

AngioDynamics (ANGO) at a 52-Week High: What's Driving It?

by Zacks Equity Research

AngioDynamics (ANGO) is optimistic about NanoKnife platform growth and the recent launch of Auryon Atherectomy.

Hologic (HOLX) Partners With Gallup on Women's Health Index

by Zacks Equity Research

Hologic (HOLX) is working to develop a global women's health index through Gallup's World Poll to improve quality of life and life expectancy of women worldwide.

Abbott (ABT) Launches Telehealth Tool for Neuromodulation

by Zacks Equity Research

Abbott (ABT) stated that Medicare will cover remote programming services as a telehealth benefit through the duration of the public health emergency.

QIAGEN (QGEN) Rides on Test Launches Amid COVID-19 Woes

by Zacks Equity Research

QIAGEN (QGEN) expands specimen types that can be used on the existing NeuMoDx SARSCoV-2 test.

ConforMIS (CFMS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of 27.27% and -0.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Conformis (CFMS) Looks Good: Stock Adds 7.7% in Session

by Zacks Equity Research

Conformis (CFMS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

ConforMIS (CFMS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of 25.00% and 0.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ConforMIS (CFMS) delivered earnings and revenue surprises of 76.92% and 32.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ConforMIS (CFMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

ConforMIS (CFMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.